Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

[cafead]

via

• The outlook for Pfizer's experimental obesity drug danuglipron is murky at best.
• Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.
• Still, Pfizer appears to be committed to carving out a stake in the huge obesity market.

article source